Art. 36 Regulation (EC) No 1901/2006 of the European Parliament and of the Council of 12 Decembe…

In forcecited 12×
1.

Where an application under Article 7 or 8 includes the results of all studies conducted in compliance with an agreed paediatric investigation plan, the holder of the patent or supplementary protection certificate shall be entitled to a six-month extension of the period referred to in Articles 13(1) and 13(2) of Regulation (EEC) No 1768/92.

The first subparagraph shall also apply where completion of the agreed paediatric investigation plan fails to lead to the authorisation of a paediatric indication, but the results of the studies conducted are reflected in the summary of product characteristics and, if appropriate, in the package leaflet of the medicinal product concerned.

2.

The inclusion in a marketing authorisation of the statement referred to in Article 28(3) shall be used for the purposes of applying paragraph 1 of this Article.

3.

Where the procedures laid down in Directive 2001/83/EC have been used, the six-month extension of the period referred to in paragraph 1 shall be granted only if the product is authorised in all Member States.

4.

Paragraphs 1, 2 and 3 shall apply to products that are protected by a supplementary protection certificate under Regulation (EEC) No 1768/92, or under a patent which qualifies for the granting of the supplementary protection certificate. They shall not apply to medicinal products designated as orphan medicinal products pursuant to Regulation (EC) No 141/2000.

5.

In the case of an application under Article 8 which leads to the authorisation of a new paediatric indication, paragraphs 1, 2 and 3 shall not apply if the applicant applies for, and obtains, a one-year extension of the period of marketing protection for the medicinal product concerned, on the grounds that this new paediatric indication brings a significant clinical benefit in comparison with existing therapies, in accordance with Article 14(11) of Regulation (EC) No 726/2004 or the fourth subparagraph of Article 10(1) of Directive 2001/83/EC.

The 10 that are cited most themselves, of 12.

  • Regulation (EC) No 469/2009 of the European Parliament and of the Council of 6 May 2009…113168Law

    … сертификата съгласно член 13, параграф 3 от настоящия регламент и член 36 от Регламент (ЕО) № 1901/2006 на Европейския парламент и на …

  • Judgment of the Court (Second Chamber) of 8 December 2011. Merck Sharp & Dohme Corp. v Deutsches Patent- und Markenamt.Decisioninterprets

    Under Article 36(1) and (4) of Regulation No 1901/2006: ‘1. Where an application under Article 7 or 8 includes the results of all studies conducted in compliance with an agreed paediatric investigation plan, the holder of the patent or …

    8 Dec 2011 · 62010CJ0125

  • Code de la propriété intellectueller617-2-1Law

    … du premier alinéa sont applicables aux demandes de prorogation présentées conformément aux dispositions de l'article 36 du règlement (CE) n° 1901/2006 du 12 décembre 2006 relatif aux médicaments à usage pédiatrique, modifiant le …

  • Judgment of the Court (Grand Chamber) of 9 July 2020. Santen SAS v Directeur général de l’Institut national de la propriété industrielle.Decision

    … 1 и 2, се удължават с шест месеца в случаите, когато се прилага член 36 от Регламент (ЕО) № 1901/2006 [на Европейския парламент и на Съвета …

    9 Jul 2020 · 62018CJ0673

  • Order of the Court (Eighth Chamber), 13 February 2014. Merck Canada Inc. v Accord Healthcare Ltd and Others.Decision

    … seines Wirksamwerdens an. (3) Die in den Absätzen 1 und 2 festgelegten Zeiträume werden im Falle der Anwendung von Artikel 36 der Verordnung (EG) Nr. 1901/2006 um sechs Monate verlängert. In diesem Fall kann die in Absatz 1 dieses …

    13 Feb 2014 · 62013CO0555

  • Judgment of the General Court (Third Chamber) of 14 December 2011. Nycomed Danmark ApS v European Medicines Agency (EMA).Decision

    Extension, as provided for in Article 36(1) of Regulation No 1901/2006, of the protection of the industrial property rights in a medicinal product in respect of which a paediatric investigation plan has been produced also constitutes a …

    14 Dec 2011 · 62009TJ0052

  • The Patents (Amendment) (EU Exit) Regulations 201952556063Law

    (1) Article 1 (interpretation) is amended as follows. (2) In paragraph (e) for “Article 36 of Regulation (EC) No 1901/2006 of the European Parliament and of the Council of 12 December 2006 on medicinal products for paediatric use”, …

  • Opinion of Advocate General Jääskinen delivered on 10 September 2015. Seattle Genetics Inc. v Österreichisches Patentamt.Decision

    In this connection, the Latvian and Lithuanian Governments refer to certain judgments of the Court of Justice according to which, in their view, the date of the ‘grant’ or the ‘obtaining’ of the first authorisation to place the …

    10 Sep 2015 · 62014CC0471

  • Opinion of Advocate General Tanchev delivered on 7 February 2018. Pfizer Ireland Pharmaceuticals, Operations Support Group v Orifarm GmbH.Decision

    In order for the paediatric extension to fall within the scope of application of the Specific Mechanism, the Contracting States did not need to expressly mention it because, by its nature, it is not another protection right besides a …

    7 Feb 2018 · 62016CC0681

  • Opinion of Mr Advocate General Bot delivered on 9 June 2011. Merck Sharp & Dohme Corp. v Deutsches Patent- und Markenamt.Decision

    Article 36 of the Paediatric Regulation is worded as follows: ‘1. Where an application under Article 7 or 8 includes the results of all studies conducted in compliance with an agreed paediatric investigation plan, the holder of the …

    9 Jun 2011 · 62010CC0125